Investigational drug · Phase 3
IKT-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "IKT-001"
First trial start
2026
Apr 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IKT-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension (PAH)
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "IKT-001" as an intervention, largest first.
- An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Pivotal-lookingRecruiting
Inhibikase TherapeuticsIndustry
NCT07365332 · 486 participants (planned) · Start Apr 23, 2026 · Primary completion Jun 2029
Drug: IKT-001; Placebo · For: Pulmonary Arterial Hypertension
Sites: Scottsdale, Arizona; Beverly Hills, California; Santa Barbara, California · 43 sites in all
- Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)Pivotal-lookingNot yet recruiting
Inhibikase TherapeuticsIndustry
NCT07632898 · 484 participants (planned) · Start Oct 23, 2026 · Primary completion Jun 30, 2030
Drug: IKT-001 · For: Pulmonary Arterial Hypertension (PAH)
Inhibikase TherapeuticsIndustry
NCT05623774 · 64 participants · Start Dec 16, 2022 · Primary completion Jun 30, 2024
Drug: Imatinib Mesylate; IkT-001Pro · For: CML
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pulmonary Arterial Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- SeralutinibPhase 32 trials
Gossamer Bio USA, Inc. · Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- NS-863Phase 22 trials
NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension
- APL-9796Phase 21 trial
Apollo Therapeutics Ltd · Pulmonary Arterial Hypertension
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
- PF-07868489Phase 21 trial
Pfizer · Pulmonary Arterial Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.